Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials
pharmafile | March 7, 2016 | News story | Research and Development, Sales and Marketing | Eli Lilly, Enbrel, ixekizumab, psoriasis
Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one week in patients with moderate-to-severe plaque psoriasis.
In the comparative UNCOVER-2 and UNCOVER-3 Phase III studies, more than 2,500 patients in 19 countries received either placebo, Enbrel (etanercept) or ixekuzimab.
The analysis evaluated the average speed of onset of clinical improvement as measured by the Psoriasis Area Severity Index (PASI) score from baseline. It also evaluated time to PASI 50 and PASI 75 among patients treated with ixekuzimab, Enbrel or placebo. The index itself measures the extent and severity of the psoriasis, including average redness, thickness and scaliness of skin lesions.
Significant statistical improvements were found in mean percentage improvement of psoriasis plaques in patients treated ixekizumab compared to Enbrel and placebo. For example, in ixekizumab, patients reached PASI 50 in as little as one week. Furthermore, the median time to PASI 75 was 30 days among ixekizumab patients compared to 85 days in those treated with Enbrel.
Craig Leonardi, lead study author and clinical professor of dermatology at St Louis University School of Medicine, comments: “Studies have shown that clinical improvement observed early during psoriasis treatment can help predict clinical response at later times. In this analysis of ixekizumab, early results were seen in patients with moderate-to-severe plaque psoriasis… According to patients and their dermatologists, rapid clearing of psoriasis plaques is one of the most important attributes for treatment success.”
Sean Murray
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
